Traditional Chinese medicine for treating pulmonary arterial hypertension

Abstract

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating pulmonary arterial hypertension, and effectively solves the problems that the western medicine for treating pulmonary arterial hypertension is limited in curative effect of symptomatic treatment and has many side effects, targeted treatment cannot fundamentally prevent the progress of a disease course and is poor in prognosis, and invasive treatment is relatively large in damage to a body, general in prognosis and high in price. According to the technical scheme, concentrated watered pills are prepared from the following raw medicinal materials by weight: 108 to 132g of astragalus membranaceus, 10 to 20g of bighead atractylodes rhizome, 27 to 33g of rhodiola rosea, 10 to 20g of trichosanthes kirilowii maxim, 27 to 33g of allium macrostemon, 10 to 20g of rhizoma pinellinae praeparata, 27 to 33g of salvia miltiorrhiza, 9 to 11g of safflower, 2.7 to 3.3 g of pseudo-ginseng, 27 to 33g of semen lepidii, 27 to 33g of white mulberry root-bark, 27 to 33g of parasitic loranthus, 45 to 55g of crude dragon bone, 45 to 55g of raw oyster shell, 54 to 66g of kudzu vine root, 45 to 55g of poria cocos, 45 to 55g of coix seed, 27 to 33g of earthworm and 9 to 11g of According to the treatment principle of tonifying qi, reducing phlegm, removing blood stasis and inducing diuresis, the traditional Chinese medicine composition can stably, durably and effectively control pulmonary arterial hypertension, improve the right heart function and control disease progression, and the life quality of patients is fundamentally improved.

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine for treating pulmonary hypertension (also known as Tiaofeiya pill). Background Art

[0002] Pulmonary hypertension (PH) refers to a pathophysiological syndrome caused by changes in the pulmonary artery vascular structure or function due to a variety of heterogeneous diseases (causes) and different pathogenesis, resulting in increased pulmonary vascular resistance and pulmonary artery pressure, which can subsequently develop into right heart failure or even death. It mainly includes five categories: arterial PH, PH caused by left heart disease, PH caused by lung disease and (or) hypoxia, chronic thromboembolic PH, and PH caused by unknown or multiple pathogenic factors. Studies have shown that the global prevalence of pulmonary hypertension is 8.5 / 1 million, and the prevalence in people over 65 years old is as high as 10%, and the 3-year survival rate is only 55% to 65%. Its early clinical symptoms are relatively hidden. As the right heart function decompensates, fatigue, shortness of breath, chest tightness and chest pain after exertion gradually appear, followed by symptoms such as syncope and lower limb or systemic edema. At present, Western medicine mainly uses drug therapy and non-drug therapy to treat PH. Drug therapy mainly includes symptomatic supportive therapy and targeted drug therapy. The symptomatic treatment has limited efficacy and many side effects. Targeted therapy cannot fundamentally prevent the progression of the disease and has a poor prognosis. Non-drug treatment mainly includes balloon pulmonary angioplasty, surgery and even lung transplantation. Its invasive treatment causes great damage to the body, has a general prognosis, and is expensive. Summary of the invention

[0003] In view of the above situation, in order to overcome the defects of the prior art, the purpose of the present invention is to provide a traditional Chinese medicine for the treatment of pulmonary arterial hypertension, which can effectively solve the problems of Western medicine treatment of pulmonary arterial hypertension, such as limited symptomatic treatment efficacy and many side effects, targeted therapy cannot fundamentally prevent the progression of the disease, poor prognosis, invasive treatment that causes great damage to the body, general prognosis, and high price.

[0004] The technical solution solved by the present invention is that the raw materials are as follows: 108-132g of astragalus, 10-20g of atractylodes, 27-33g of rhodiola, 10-20g of trichosanthes, 27-33g of Allium macrostemon, 10-20g of pinellia, 27-33g of salvia miltiorrhiza, 9-11g of safflower, 2.7-3.3g of notoginseng, 27-33g of scutellaria, 27-33g of mulberry bark, 27-33g of parasitic plant, 45-55g of raw dragon bone, 45-55g of raw oyster, 54-66g of kudzu root, 45-55g of poria, 45-55g of coix seed, 27-33g of earthworm and 9-11g of cassia twig as raw materials, and the concentrated water pills are prepared according to a conventional method.

[0005] The present invention is formulated based on the treatment principles of invigorating qi and resolving phlegm, removing blood stasis and promoting diuresis, and can stably, durably and effectively control pulmonary hypertension, improve right heart function, control the progression of the disease, and fundamentally improve the patient's quality of life. DETAILED DESCRIPTION

[0006] The specific implementation of the present invention is described in detail below in conjunction with the embodiments.

[0007] Example 1

[0008] The invention is prepared from the following raw materials by weight: 120g of astragalus, 15g of atractylodes, 30g of rhodiola, 15g of trichosanthes, 30g of allium macrostemon, 15g of pinellia, 30g of salvia miltiorrhiza, 10g of safflower, 3g of notoginseng, 30g of scutellaria baicalensis, 30g of mulberry bark, 30g of parasitic plant, 50g of raw dragon bone, 50g of raw oyster, 60g of kudzu root, 50g of tuckahoe, 50g of coix seed, 30g of earthworm and 10g of cassia twig, and is prepared into concentrated water pills according to a conventional method.

[0009] Example 2

[0010] The invention is prepared from the following raw materials by weight: 108g of astragalus, 10g of atractylodes, 27g of rhodiola, 10g of trichosanthes, 27g of Allium macrostemon, 10g of pinellia, 27g of salvia miltiorrhiza, 9g of safflower, 2.7g of notoginseng, 27g of scutellaria, 27g of mulberry bark, 27g of parasitic plant, 45g of raw dragon bone, 45g of raw oyster, 54g of kudzu root, 45g of tuckahoe, 45g of coix seed, 27g of earthworm and 9g of cassia twig, and is prepared into concentrated water pills according to a conventional method.

[0011] Example 3

[0012] The invention is prepared from the following raw materials by weight: 132g of astragalus, 20g of atractylodes, 33g of rhodiola, 20g of trichosanthes, 33g of allium macrostemon, 20g of pinellia, 33g of salvia miltiorrhiza, 11g of safflower, 3.3g of notoginseng, 33g of scutellaria, 33g of mulberry bark, 33g of parasitic plant, 55g of raw dragon bone, 55g of raw oyster, 66g of kudzu root, 55g of tuckahoe, 55g of coix seed, 33g of earthworm and 11g of cassia twig, and is prepared into concentrated water pills according to a conventional method.

[0013] The above-mentioned drugs, wherein:

[0014] Astragalus: replenishes qi and raises yang, promotes diuresis and reduces swelling, and benefits the spleen and lung qi;

[0015] Atractylodes macrocephala: It has the effects of replenishing qi and strengthening the spleen, drying dampness and promoting diuresis, and stopping sweating;

[0016] Rhodiola rosea: It can promote blood circulation and stop bleeding, clear the lungs and relieve coughs, and has the effects of replenishing qi and clearing the lungs, improving intelligence and nourishing the heart, and dispersing blood stasis and reducing swelling;

[0017] Trichosanthes: clears heat and removes phlegm, relieves chest tightness and resolves stagnation, moistens the intestines, and is used for cough due to lung heat, turbid yellow and thick phlegm, chest pain and heartache;

[0018] Xiebai: regulates qi, relieves chest tightness, promotes yang, and disperses stagnation;

[0019] French Pinellia: Drying dampness and resolving phlegm, used for cough and asthma due to excessive phlegm, dizziness and palpitations due to phlegm and fluid, dizziness due to wind and phlegm, and headache due to phlegm and syncope.

[0020] Danshen: promotes blood circulation, removes blood stasis, soothes the mind, discharges pus, and relieves pain;

[0021] Safflower: promotes blood circulation and menstruation; removes blood stasis and relieves pain;

[0022] Panax notoginseng: stops bleeding, disperses blood stasis, reduces swelling, and relieves pain;

[0023] Tinglizi: purging the lungs and lowering qi; removing phlegm and relieving asthma; promoting diuresis and reducing swelling; purging and expelling pathogens;

[0024] Morus alba bark: purging the lungs and relieving asthma, promoting water circulation and reducing swelling;

[0025] Mulberry parasite: nourishes the liver and kidneys, strengthens the tendons and bones, eliminates rheumatism, dredges the meridians, and replenishes blood;

[0026] Raw dragon bone: calms nerves and soothes the mind, stops sweating and consolidates semen, stops bleeding and astringes the intestines, promotes tissue regeneration and heals sores;

[0027] Raw oysters: soothe the liver and suppress yang; calm the mind; soften and disperse lumps; astringe and consolidate;

[0028] Pueraria root: relieves muscle tension and reduces fever; promotes the secretion of qi and clears away heat; promotes the production of body fluids and quenches thirst; promotes yang and stops diarrhea;

[0029] Poria: dissipates dampness and promotes diuresis, benefits the spleen and stomach, and calms the mind;

[0030] Coix seeds: Strengthen the spleen and eliminate dampness, eliminate numbness and stop diarrhea, clear away heat and expel pus;

[0031] Earthworm: clears the qi and stops spasms, calms the liver and extinguishes wind, dredges the meridians and activates the collaterals, relieves asthma and promotes urination;

[0032] Cinnamon twig: induces sweat and relieves muscles, warms and unclogs the meridians, assists in the transformation of yang and qi, and balances and descends qi.

[0033] It can be seen from the above medicines that the present invention uses tonifying qi and resolving phlegm, removing blood stasis and promoting diuresis as the main treatment method. The whole prescription is well matched, and it is used to strengthen the body and eliminate evil at the same time. It focuses on tonifying the qi of the heart and lungs to promote blood circulation, removing phlegm and removing blood stasis to unclog blood vessels, warming yang and promoting diuresis to treat its symptoms, and has achieved significant therapeutic effects through clinical application in the treatment of pulmonary hypertension. The relevant experimental data are as follows: 1 General information

[0034] A total of 58 patients who met the inclusion criteria and visited the outpatient department of the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from January 2013 to January 2023 were screened, and the methods of follow-up and data collection were used to conduct a retrospective study and observe the efficacy indicators before and after treatment. Among them, there were 30 males and 28 females, with an average age of (61±12) years old. The treatment duration was 5-8 months, and the average treatment duration was 6.5±1.4 months. Among them, 15 cases had a history of smoking, 24 cases had a history of drinking, 34 cases had heart failure, 12 cases had valvular heart disease, 9 cases had chronic obstructive pulmonary disease, 3 cases had chronic thromboembolic pulmonary hypertension, 19 cases had coronary heart disease, 18 cases had atrial fibrillation, 12 cases had hypertension, and 8 cases had diabetes. There were 3 cases of stroke.

[0035] 2 Observation methods

[0036] 2.1 Diagnostic criteria

[0037] 2.1.1 TCM diagnostic criteria:

[0038] Formulated with reference to the "Guidelines for Clinical Research of New Chinese Medicines" and "Practical Chinese Medicine Diagnostics";

[0039] 2.1.2 Western medicine diagnostic criteria:

[0040] Referring to the Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in China (2022 Edition), pulmonary hypertension is suspected if the pulmonary artery systolic pressure (PASP) measured by echocardiography at rest is above 40 mmHg; movement is limited, shortness of breath, fatigue, chest pain or near syncope. A pulmonary artery systolic pressure of 40 mmHg-49 mmHg is diagnosed as mild, 50 mmHg-69 mmHg as moderate, and above 70 mmHg as severe.

[0041] 2.1.3 TCM symptom diagnosis criteria:

[0042] Main symptoms: shortness of breath, fatigue, chest pain.

[0043] Secondary symptoms: palpitations, shortness of breath, blackouts, near-syncope, swelling of the lower limbs or the whole body, vomiting of sputum, sticky phlegm in the mouth, abdominal distension, dark purple lips, etc.

[0044] Tongue appearance: The tongue is dull, with scattered ecchymoses or petechiae on the tongue surface, and the veins at the bottom of the tongue are dark purple; the tongue coating is greasy or slippery.

[0045] Pulse: The pulse is thin and weak, or deep, thin, astringent and slippery.

[0046] Diagnostic criteria: The main symptoms and three or more secondary symptoms are present, and the diagnosis can be made based on the tongue and pulse.

[0047] 2.2 Criteria for determining efficacy

[0048] 2.2.1 Clinical efficacy evaluation criteria, based on the patient's symptoms and signs, refer to the WHO functional classification of pulmonary hypertension in the "Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in China (2022 Edition)":

[0049] (1) Marked effect: Major symptoms such as shortness of breath and chest pain disappear or reach the marked effect standard, and pulmonary hypertension decreases from severe to mild and normal or from moderate to normal.

[0050] (2) Effective: Major symptoms such as shortness of breath and chest pain disappear or reach effective standards, and pulmonary hypertension decreases from severe to moderate or from moderate to mild.

[0051] (3) Ineffective: There was no improvement in the main symptoms such as shortness of breath and chest pain, and pulmonary hypertension was basically the same as before treatment.

[0052] When making comprehensive diagnosis and treatment judgments, if the efficacy of the main symptoms such as shortness of breath and chest pain is inconsistent with the efficacy of pulmonary hypertension, the lower efficacy result should be taken as the comprehensive efficacy.

[0053] 2.2.2 TCM syndrome score evaluation criteria using the nimodipine method

[0054] Therapeutic index (n) = (total score before treatment - total score after treatment) / total score before treatment × 100%;

[0055] (1) Significantly effective: clinical symptoms and signs were significantly improved, and the syndrome score was reduced by ≥70%;

[0056] (2) Effective: clinical symptoms and signs improved, and the syndrome score decreased by ≥30%;

[0057] (3) Ineffective: There is no significant improvement in clinical symptoms and signs, or they may even worsen, and the symptom score decreases by <30%.

[0058] 2.3 Inclusion criteria

[0059] (1) Patients with pulmonary hypertension who meet the above diagnostic criteria and belong to categories I-IV, including arterial pulmonary hypertension, pulmonary hypertension caused by left heart disease, pulmonary hypertension caused by lung disease, and chronic thromboembolic pulmonary hypertension;

[0060] (2) patients with WHO pulmonary hypertension functional classification of II-III;

[0061] (3) Meet the TCM syndrome differentiation criteria of qi deficiency, phlegm, blood stasis and water retention;

[0062] (4) Aged 18 to 75 years (inclusive), with a disease course of at least 1 year;

[0063] (5) Patients who have not used other traditional Chinese medicine methods and targeted drugs or targeted drug treatment regimens for at least 1 month in the past month; (6) Patients who have been treated for 5-8 consecutive months without stopping medication for more than 1 week;

[0064] (7) Those with complete clinical data (liver and kidney function before and after treatment).

[0065] 2.4 Exclusion criteria

[0066] (1) Patients with acute exacerbation of chronic heart failure, acute myocardial infarction, coronary revascularization, cardiac resynchronization therapy, acute exacerbation of chronic obstructive pulmonary disease, or concurrent pulmonary infection;

[0067] (2) Combined with malignant tumors;

[0068] (3) patients with right ventricular outflow tract obstruction;

[0069] (4) Patients with congenital heart disease;

[0070] (5) Patients with severe liver and kidney damage;

[0071] (6) Those with mental disorders and poor compliance;

[0072] (7) Pregnant or lactating women;

[0073] (8) Patients with serious diseases such as hyperthyroidism and malignant arrhythmia;

[0074] (9) Those who are known to have adverse reactions to the drugs used in the study.

[0075] 2.5 Treatment methods

[0076] (1) Oral administration of the present invention, 6 grams each time, 3 times a day, with warm water. Conventional drugs for treating pulmonary hypertension with pulmonary vasodilators, cardiotonic, diuretic and anticoagulant agents, and other drugs for treating complications remain unchanged.

[0077] 2.6 Safety evaluation indicators

[0078] (1) Liver function ALT, AST

[0079] (2) Renal function BUN, CR

[0080] (3) Coagulation function PT, INR

[0081] 2.7 Efficacy Observation Indicators

[0082] (1) Measurement of pulmonary artery systolic pressure before and after treatment: All patients underwent cardiac ultrasound examination by the same experienced cardiac ultrasound medical worker at the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine before and after treatment. Before measuring blood pressure, the patient was communicated with to relax and stabilize his mood. Specific method: Philips IE33 cardiac color Doppler ultrasound diagnostic instrument was used for measurement. The patient was asked to lie on his left side and breathe calmly. The probe was placed between the 3rd and 4th intercostal spaces on the left side of the sternum and under the xiphoid process. The peak flow velocity of tricuspid regurgitation (Vmax) and right atrial pressure (RAP) were recorded, and the pulmonary artery systolic pressure (PASP = 4Vmax) was calculated. 2 + right atrial pressure).

[0083] (2) 6-minute walk distance (6MWD) and Borg dyspnea score: refer to the "6-minute walk test guide". After the test, record the Borg dyspnea score.

[0084] (3) Comparison of efficacy of TCM syndrome score: Record once before and after treatment according to the TCM syndrome score standard.

[0085] (4) Echocardiographic indicators, including left ventricular ejection fraction and right ventricular internal diameter, are measured simultaneously with pulmonary artery systolic pressure using the same method as above. (5) NT-proBNP level. Right heart failure is the terminal stage of pulmonary hypertension, and NT-proBNP is an important indicator of heart failure and an examination indicator for predicting patient mortality and serious adverse events. The release of BNP is associated with ventricular dysfunction and myocardial dilation. When the myocardium dilates, the level of NT-proBNP release increases.

[0086] (6) Blood biochemical examination: liver function, kidney function, and coagulation function.

[0087] 2.9 Statistical methods

[0088] SPSS 19.0 statistical software was used to process the data. The quantitative data that conformed to the normal distribution were described by mean ± standard deviation (x ± s); the paired t test was used when the quantitative data before and after treatment conformed to the normal distribution and the variance was equal, and the rank sum test was used for non-normal distribution and qualitative data. P < 0.05 was considered to be statistically significant.

[0089] 3 Results

[0090] 3.1 Safety evaluation indicators

[0091] According to the safety indicators detected before and after treatment, the changes in liver function, kidney function and coagulation function before and after treatment were not statistically significant (P>0.05), and no adverse reactions and toxic side effects were found. This shows that the present invention has good safety in treating pulmonary hypertension (Qi deficiency, phlegm, blood stasis and water retention syndrome). See Table 1 for details.

[0092] Table 1 Comparison of safety indicators before and after treatment

[0093]

[0094] 3.2 Comparison of efficacy of TCM syndrome score

[0095] The criteria for judging the TCM syndrome score of the present invention for treating pulmonary hypertension are shown in Table 2. After data analysis, the total effective rate after treatment was 96.55%, and P < 0.05 was obtained. The TCM syndrome score before and after treatment was significantly different, which was statistically significant. This shows that the TCM syndrome score is significantly improved. See Table 3-4 for details.

[0096] Table 2: Standards for judging the TCM syndrome score for treating pulmonary hypertension in the present invention

[0097]

[0098]

[0099] a: The scoring standards are 0, 3, 6, 9; b: The scoring standards are 0, 1, 2, 3; c: The scoring standards are 0, 1.

[0100] Table 3 Comparison of TCM syndrome scores before and after treatment

[0101]

[0102] Table 4 TCM syndrome score evaluation of efficacy

[0103]

[0104] 3.4 Comparison of pulmonary artery systolic pressure before and after treatment

[0105] The comparison of pulmonary artery systolic pressure in the group before and after treatment was in accordance with normal distribution by normality test; the comparison of blood pressure in the group was compared by paired sample t test, P < 0.05, indicating that compared with before taking the Chinese medicine of the present invention, the pulmonary artery systolic pressure can be significantly reduced after taking the Chinese medicine of the present invention, as shown in Table 5. After data analysis, it was found that the total effective rate of blood pressure reduction after taking the Chinese medicine of the present invention was 93.1%, indicating that the Chinese medicine of the present invention has a significant effect in improving the pulmonary artery systolic pressure of patients, as shown in Table 6.

[0106] Table 5 Comparison of pulmonary artery systolic pressure before and after treatment (mmHg)

[0107]

[0108] Table 6 Evaluation of therapeutic effect of pulmonary artery systolic pressure after treatment

[0109]

[0110] Table 7 Evaluation of the efficacy of 6MWD and Borg dyspnea score after treatment

[0111]

[0112] 3.5 Comparison of changes before and after cardiac ultrasound treatment

[0113] After treatment, the left ventricular ejection fraction (LVEF) increased from 45.93±2.32% to 54.34±3.23%, and the right ventricular internal diameter (RV) decreased from 33.54±2.34mm to 29.13±1.87mm; the rank sum test showed that P<0.05, indicating a statistically significant difference. The specific comparison data are shown in Table 8.

[0114] Table 8 Comparison of cardiac ultrasound before and after treatment

[0115]

[0116] Comparison of NT-proBNP results

[0117] The data obtained by checking NT-proBNP before and after treatment of the included patients were statistically analyzed and showed that the baseline value after treatment decreased from 1178.70±534.23 to 534.21±293.17, a decrease of 644.49±313.27 compared with the baseline value. The comparison of NT-proBNP values ​​before and after treatment was P<0.05, and the difference was statistically significant. See Table 5 for details.

[0118] Table 5 Changes of NT-proBNP before and after treatment (ng / L)

[0119]

[0120] 4 Discussion

[0121] Pulmonary hypertension is a disease or pathophysiological syndrome caused by a variety of clinical conditions, which will eventually cause irreversible right heart failure, and its morbidity, disability rate and mortality rate are all at a high level, seriously threatening human life and health. Pulmonary hypertension is not an independent disease, but a result caused by a variety of disease factors, so the use of Western medicine lacks specificity and the clinical efficacy is poor. Traditional Chinese medicine advocates a holistic concept, starting from the whole, and treating the disease based on syndrome differentiation. After long-term research and experiments, this application believes that the main cause of pulmonary hypertension is deficiency of qi in the heart and lungs, which makes the lungs facing all the meridians and the heart governing the blood vessels dysfunction, and phlegm and blood stasis block the heart and lungs. Over time, blood is not good, which is water, and water stops in the heart and lungs as a sign. Finally, the present invention's Tiaofei Ya pill was developed. The present invention treats pulmonary hypertension through multi-component synergy, multi-target drug efficacy, and multi-pathway disease regulation, effectively reducing pulmonary hypertension, improving right heart function, and controlling the progression of the disease, fundamentally improving the patient's quality of life. The present application believes that the increase in pulmonary artery systolic pressure is the disease resistance and regulatory response made by the human body to overcome the disorder of qi and blood circulation, and proposes the treatment idea of ​​"adjusting rather than directly lowering the pulmonary hypertension, focusing on taking advantage of the situation" for the treatment of pulmonary hypertension. Therefore, although the pulmonary artery pressure is high, it is not suitable to directly lower the blood pressure. In traditional Chinese medicine treatment, it is necessary to take advantage of the situation, resolve phlegm, remove blood stasis and promote diuresis, dredge qi and blood, regulate blood pressure and stabilize blood pressure. According to its basic pathogenesis, "replenishing qi and resolving phlegm, removing blood stasis and promoting diuresis" is proposed as a treatment method, and the present invention's Tiaofeiya pill is gradually formed, which has significant clinical efficacy.

[0122] The present application believes that the main pathogenesis of pulmonary hypertension is deficiency of the root and excess of the superficial, and a mixture of deficiency and excess, with qi deficiency as the root and phlegm and blood stasis as the superficial. Therefore, the present invention takes tonifying qi and resolving phlegm, removing blood stasis and promoting diuresis as the treatment principles and formulates a prescription. In the prescription, astragalus and white atractylodes can invigorate qi and strengthen the spleen, cultivate soil to produce gold, and rhodiola rosea can invigorate qi and activate blood circulation, dredge meridians and relieve asthma. The three medicines are used together to regulate the qi and blood of the heart and lungs as the main medicine; among them, trichosanthes, allium macrostemon, pinellia ternata and coix seed can warm and promote heart yang, relieve chest tightness, resolve phlegm and eliminate dampness; salvia miltiorrhiza, safflower and panax notoginseng can promote blood circulation and remove blood stasis without leaving blood stasis; mulberry bark and sedum seed can purge the lungs, relieve asthma and promote diuresis; Poria and cinnamon twig come from the Ling Gui Zhu Gan Decoction in Treatise on Febrile Diseases, which can warm yang, resolve phlegm and promote diuresis as the ministerial medicine; kudzu root, earthworm and mistletoe can invigorate the liver and kidney, dredge meridians and activate collaterals to relieve asthma, and raw dragon bone and raw oyster can calm the nerves and tranquilize the mind as the adjuvant medicine. The whole prescription is well matched, and it is used to strengthen the body and eliminate evil at the same time. It focuses on replenishing the Qi of the heart and lungs to promote blood circulation, resolving phlegm and removing blood stasis to unclog blood vessels, and warming yang and promoting diuresis to treat its symptoms. In short, the present invention can treat pulmonary hypertension by replenishing Qi and resolving phlegm, removing blood stasis and promoting diuresis, can significantly improve clinical symptoms, fundamentally improve the patient's cardiac function and treat right ventricular heart failure, control the progression of the disease, improve the patient's quality of life, and is safe and reliable to use, and is worthy of clinical application.

Claims

1. A Chinese medicine for treating pulmonary hypertension, characterized in that: The medicine is made from the following raw materials measured by weight: 108-132g of Astragalus, 10-20g of Atractylodes, 27-33g of Rhodiola, 10-20g of Trichosanthes, 27-33g of Allium macrostemon, 10-20g of Pinellia, 27-33g of Salvia miltiorrhiza, 9-11g of Carthamus tinctorius, 2.7-3.3g of Notoginseng, 27-33g of Lepidium membranaceus, 27-33g of Morus alba bark, 27-33g of Viscum album, 45-55g of raw Dragon Bone, 45-55g of raw Oyster, 54-66g of Pueraria root, 45-55g of Poria, 45-55g of Coix seeds, 27-33g of Pheretima and 9-11g of Cinnamomum cassia twig.

2. A Chinese medicine for treating pulmonary hypertension according to claim 1, characterized in that: The raw materials are as follows: 120g of Astragalus, 15g of Atractylodes, 30g of Rhodiola, 15g of Trichosanthes, 30g of Allium macrostemon, 15g of Pinellia, 30g of Salvia miltiorrhiza, 10g of Carthamus tinctorius, 3g of Notoginseng, 30g of Lepidium, 30g of Morus alba, 30g of Viscum album, 50g of raw Dragon Bone, 50g of raw Oyster, 60g of Pueraria, 50g of Poria, 50g of Coix seeds, 30g of Pheretima and 10g of Cinnamon twig.

3. A Chinese medicine for treating pulmonary hypertension according to claim 1, characterized in that: The medicine is made from the following raw materials measured by weight: 108g of Astragalus, 10g of Atractylodes, 27g of Rhodiola, 10g of Trichosanthes, 27g of Allium macrostemon, 10g of Pinellia, 27g of Salvia miltiorrhiza, 9g of Carthamus tinctorius, 2.7g of Panax notoginseng, 27g of Lepidium membranaceus, 27g of Morus alba bark, 27g of Viscum album, 45g of raw dragon bone, 45g of raw oyster, 54g of Pueraria root, 45g of Poria, 45g of Coix seed, 27g of Pheretima and 9g of Cassia twig.

4. A Chinese medicine for treating pulmonary hypertension according to claim 1, characterized in that: The medicine is made from the following raw materials measured by weight: 132g of Astragalus, 20g of Atractylodes, 33g of Rhodiola, 20g of Trichosanthes, 33g of Allium macrostemon, 20g of Pinellia, 33g of Salvia miltiorrhiza, 11g of Carthamus tinctorius, 3.3g of Panax notoginseng, 33g of Lepidium officinale, 33g of Morus alba bark, 33g of Viscum album, 55g of raw dragon bone, 55g of raw oyster, 66g of Pueraria root, 55g of Poria, 55g of Coix seed, 33g of Pheretima and 11g of Cassia twig.

Images